Penbutolol


Full Generic Medicine Info
Dosage/Direction for Use

Oral
Hypertension
Adult: Initially, 20 mg daily, increased to 40-80 mg/day if needed.
Administration
May be taken with or without food.
Contraindications
AV block (2nd and 3rd degree), sinus bradycardia, bronchial asthma, cardiogenic shock.
Special Precautions
Bronchospastic disease, compensated heart failure, DM, myasthenia gravis, untreated phaeochromocytoma, peripheral vascular disease including Raynaud's disease. May mask signs and symptoms of hyperthyroidism and acute hypoglycaemia. Avoid abrupt withdrawal as it may precipitate thyroid storm, exacerbate angina, HTN and MI. Patients undergoing surgery involving general anaesth. Pregnancy and lactation. Monitoring Parameters Monitor BP and heart rate.
Adverse Reactions
Headache, dizziness, fatigue, insomnia, asthenia, arrhythmia, diaphoresis, CHF, nausea, diarrhoea, dyspepsia, upper resp tract infection, dyspnoea, cough, chest and limb pain, excessive sweating, impotence.
Overdosage
Symptoms: Bradycardia, hypotension, bronchospasm and acute cardiac failure. Management: Consider gastric emptying. IV atropine sulfate may be given to induce vagal blockade, and if bradycardia persists, administer IV isoproterenol HCl cautiously. For hypotension, sympathomimetic drugs (e.g. dobutamine, dopamine, levarterenol) may be given. IV glucagon may be useful in refractory cases. For bronchospasm, a β2-agonist and/or IV aminophylline may be considered.
Drug Interactions
Concomitant use w/ digitalis glycosides may increase the risk of bradycardia. Hypoglycaemic effects of insulin and antidiabetics may be prolonged. Coadministration w/ Ca antagonist may lead to synergistic hypotensive effects, bradycardia and arrhythmias. Additive effects w/ anaesth agents that depress the myocardium (e.g. cyclopropane, ether, trichloroethylene). Catecholamine-depleting drugs (e.g. reserpine) may enhance hypotensive effects. May enhance the rebound hypertensive effect of clonidine.
Action
Penbutolol is a non-cardioselective β-blocker w/ some intrinsic sympathomimetic activity but lacks membrane-stabilising properties.
Onset: 1.5-3 hr.
Duration: >20 hr.
Absorption: Readily absorbed from GI tract. Bioavailability: Approx 100%. Time to peak plasma concentration: Approx 1-3 hr.
Distribution: Plasma protein binding: 80-98%.
Metabolism: Undergoes extensive hepatic metabolism via hydroxylation and glucuronidation.
Excretion: Via urine (as metabolites). Elimination half-life: Approx 20 hr.
Storage
Oral: Store between 20-25°C. Protect from light.
CIMS Class
Beta-Blockers
ATC Classification
C07AA23 - penbutolol ; Belongs to the class of non-selective beta-blocking agents. Used in the treatment of cardiovascular diseases.
Disclaimer: This information is independently developed by CIMS based on penbutolol from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in